Structure activity relationship for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene

被引：38

作者：

Overk, Cassia R.

Peng, Kuan-Wei

Asghodom, Rezene T.

Kastrati, Irida

Lantvit, Daniel D.

Qin, Zhihui

Frasor, Jonna

Bolton, Judy L.

Thatcher, Gregory R. J.

机构：

[1] Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612

[2] Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago

来源：

CHEMMEDCHEM | 2007年 / 2卷 / 10期

关键词：

D O I：

10.1002/cmdc.200700104

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The search for the "ideal" selective estrogen receptor modulator (SERM) as a substitute for hormone replacement therapy (HRT) or use in cancer chemoprevention has focused on optimization of estrogen receptor (ER) ligand binding. Based on the clinical and preclinical benzothiophene SERMs, raloxifene and arzoxifene, a family of SERMs has been developed to modulate activity and oxidative lability. Antiestrogenic potency measured in human endometrial and breast cancer cells, and ER ligand binding data were correlated and seen to provide a guide to SERM design only when viewed in toto. The in vitro studies were extended to the juvenile rat model, in which the desired antiestrogenic profile and putative cardiovascular benefits of SERMs were observed.

引用

页码：1520 / 1526

页数：7

共 31 条

[1] Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women [J].

Barrett-Connor, Elizabeth ;

Mosca, Lori ;

Collins, Peter ;

Geiger, Mary Jane ;

Grady, Deborah ;

Kornitzer, Marcel ;

McNabb, Michelle A. ;

Wenger, Nanette K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) :125-137

[2] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer [J].

Bergman, L ;

Beelen, MLR ;

Gallee, MPW ;

Hollema, H ;

Benraadt, J ;

van Leeuwen, FE .

LANCET, 2000, 356 (9233) :881-887

[3] Arzoxifene as therapy for endometrial cancer [J].

Burke, TW ;

Walker, CL .

GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :S40-S46

[4]

Dardes RC, 2001, CLIN CANCER RES, V7, P4149

[5] Bioactivation of selective estrogen receptor modulators (SERMs) [J].

Dowers, Tamara S. ;

Qin, Zhi-Hui ;

Thatcher, Gregory R. J. ;

Bolton, Judy L. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (09) :1125-1137

[6] Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype [J].

Frasor, J ;

Danes, JM ;

Komm, B ;

Chang, KCN ;

Lyttle, CR ;

Katzenellenbogen, BS .

ENDOCRINOLOGY, 2003, 144 (10) :4562-4574

[7] SERMs in chemoprevention of breast cancer [J].

Gasco, M ;

Argusti, A ;

Bonanni, B ;

Decensi, A .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (13) :1980-1989

[8] Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene [J].

Grese, TA ;

Cho, S ;

Finley, DR ;

Godfrey, AG ;

Jones, CD ;

Lugar, CW ;

Martin, MJ ;

Matsumoto, K ;

Pennington, LD ;

Winter, MA ;

Adrian, MD ;

Cole, HW ;

Magee, DE ;

Phillips, DL ;

Rowley, ER ;

Short, LL ;

Glasebrook, AL ;

Bryant, HU .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (02) :146-167

[9] Molecular determinants of tissue selectivity in estrogen receptor modulators [J].

Grese, TA ;

Sluka, JP ;

Bryant, HU ;

Cullinan, GJ ;

Glasebrook, AL ;

Jones, CD ;

Matsumoto, K ;

Palkowitz, AD ;

Sato, M ;

Termine, JD ;

Winter, MA ;

Yang, NN ;

Dodge, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :14105-14110

[10] MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTI-ESTROGENIC ACTIVITY [J].

JORDAN, VC ;

COLLINS, MM ;

ROWSBY, L ;

PRESTWICH, G .

JOURNAL OF ENDOCRINOLOGY, 1977, 75 (02) :305-316

← 1 2 3 4 →